MGCD0103 (MG-0103)

MGCD0103 · Mirati Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MGCD0103 (MG-0103), covering 2015-07-01 to 2015-07-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]